LAURA — Osimertinib Following Chemoradiation in Stage III Unresectable EGFR-Mutated NSCLC

Phase 3 · 2024 · Non-Small Cell Lung Cancer

Design

Randomized double-blind consolidation osimertinib vs placebo after definitive chemoradiation.

Population

Stage III unresectable EGFR-mutated (exon 19 del or L858R) NSCLC without progression after chemoradiation.

Primary Endpoint

progression-free survival (PFS)

Key Result

Median PFS 39.1 vs 5.6 mo (HR 0.16).

Guideline Impact

NCCN category 1 consolidation osimertinib for unresectable stage III EGFR-mutant NSCLC